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E-mail address: farissami@yahoo.comApoptosis may play a crucial role in the pathogenesis of late diabetic neuropathy. We determine the role
of Fas mediated apoptosis in the aetiopathogenesis of diabetic neuropathy, by measurement of apoptosis
markers, induction of apoptosis by Fas and/or serum and correlate the level of soluble Fas (marker of
apoptosis) with the nerve conduction study. Furthermore, we elucidate the role of apoptosis inhibition
in prevention of diabetic neuropathy by the Fas blocker (ZB4).
There was signiﬁcant increase in the sFas serum level in diabetics with neuropathy as compared to the
controls and diabetic patients without neuropathy (p < 0.005). All parameters of the motor median nerve
conduction study showed signiﬁcant correlation with the serum sFas levels, especially the nerve conduc-
tion velocity (r = 0.60, p < 0.01). Cells treated with the serum of diabetic patients with neuropathy
showed signiﬁcantly higher percentages of early and late apoptosis (p < 0.05) compared to the negative
control. A 500ng/mL Fas blocker (ZB4), antagonistic anti-Fas antibody caused signiﬁcantly lower levels of
early and late apoptosis (p < 0.025) compared to serum of diabetic patients with neuropathy treatment.
In conclusion, Fas-mediated apoptosis of the neuronal cell line is responsible for the degradation of the
neurons in patients with diabetic neuropathy and provides evidence for the involvement of the receptor
pathway in Fas-mediated apoptosis of these cells. Thus, targeting and inhibiting Fas receptor offers an
option for diabetic neuropathy therapy.
 2009 International Journal of Diabetes Mellitus. Published by Elsevier Ltd.
Open access under CC BY-NC-ND license.Type 2 diabetes is a metabolic disease, associated with a wide
range of co-morbidities and complications, including retinopathy
and loss of vision, nephropathy and end-stage renal disease,
peripheral neuropathy, cardiovascular diseases as well as lower
extremity amputations due to diabetic foot. A high prevalence rate
of diabetes mellitus was noted in Saudis (23.7%) [1]. Since diabetic
neuropathy (DN) is a common complication of diabetes and occurs
in approximately 50% of diabetic patients [2], this complication
was selected for investigation in the current study.
There is evidence to suggest that acquired immunity and
inﬂammation as well as oxidative stress and apoptosis, may play
a crucial role in the pathogenesis of late diabetic neuropathy [3].
Although high levels of sFas (marker of apoptosis) were de-
tected in the serum of diabetic patients with neuropathy, it is
not known whether this high level of serum of speciﬁc sFas can in-
duce apoptosis in the human neuronal cell line. Furthermore, there
is no study which shows any correlation between nerve conduc-
tion study and markers of apoptosis in diabetic neuropathy; such
correlation may be useful in the future progress of diabetic neurop-ellitus. Published by Elsevier Ltd. Oathy. Besides, no previous study investigated the inhibition of Fas-
mediated apoptosis in neuronal cell line, by Fas blocker.
The objectives of the present study were: First, to evaluate and
select diabetic patients with neuropathy by nerve conduction
study. Second, to determine the role of Fas mediated apoptosis in
the aetiopathogenesis of diabetic neuropathy, by measurement of
apoptosis markers, induction of apoptosis by Fas and/or serum,
to correlate the level of soluble Fas (marker of apoptosis) with
the nerve conduction study. Third, to elucidate the role of apopto-
sis inhibition in prevention of diabetic neuropathy by the Fas
blocker (ZB4).
A prospective clinical and experimental study was conducted.
The clinical part was mainly in the form of nerve conduction study
to evaluate and select diabetic patients with neuropathy. This was
carried out in 28 healthy subjects (19 males and 9 females) aged
23–55 years, who served as controls. The median, common pero-
neal and sural nerves were stimulated bilaterally by means of
the Nicolet Spirit system. Nerve conduction study was also carried
out in 55 diabetic patients (18 males and 37 females) aged 13–57
years, using the same equipment as used in the study of control
subjects. Sera of sFas and sFasL levels were measured by enzyme
linked immunosorbent assay (ELISA) method [4]. Furthermore, ser-
um and Fas blocker (ZB4) were used to induce and inhibitpen access under CC BY-NC-ND license.
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sured by ﬂow cytometry. The correlation between the level of mar-
ker of apoptosis (sFas) and the nerve conduction study was worked
out.
The ﬁndings of the present study showed that there was a signif-
icant increase of serum glucose and glycosylated HbA1c in diabetic
patients ðp < 0:05Þ. There was a signiﬁcant difference between all
the study groups in motor median nerve, amplitude, latency and
conduction velocity ðp < 0:05Þ. Also there was a signiﬁcant differ-
ence in median nerve, sensory amplitude and conduction velocity
in diabetic patients with and without neuropathy compared to con-
trols ðp < 0:05Þ. Concerning sural nerve, there were signiﬁcant
changes in sural nerve latency and conduction velocity in patients
with neuropathy, as compared to control as well as to diabetic pa-
tients without neuropathy ðp < 0:05Þ. Common peroneal motor
conduction velocity decreased signiﬁcantly in neuropathy patients
as compared to the controls ðp < 0:05Þ. However, there was no sig-
niﬁcant difference in the sensory latency of median nerve, ampli-
tude or sural nerve as well as common peroneal nerve amplitude
and latency between all the study groups.
The diabetic patients were classiﬁed according to the result of
nerve conduction velocities and distal latencies into 28 diabetic pa-
tients with and 27 without neuropathy.
There was a signiﬁcant increase in the sFas serum level in dia-
betics with neuropathy as compared to the controls and diabetic
patients without neuropathy ðp < 0:005Þ. Thus, serum sFas levels
as well as conduction velocity of median nerve in diabetes could
be considered as an apoptotic diagnostic marker for diabetic
neuropathy.
The mean of serum sFas in diabetic patients with or without
neuropathy positively correlated with the control ðr ¼ 0:68;
p < 0:01Þ. There were no signiﬁcant differences between serum
sFasL in different groups.
All parameters of the motor median nerve conduction study
showed signiﬁcant correlation with the serum sFas levels, espe-
cially the nerve conduction velocity ðr ¼ 0:60; p < 0:01Þ.
Cells treated with the serum of diabetic patients with neuropa-
thy showed signiﬁcantly higher percentages of early and late apop-
tosis ðp < 0:05Þ compared to the negative control. A 500 ng/ml Fas
blocker (ZB4), antagonistic anti-Fas antibody caused signiﬁcantlylower levels of early and late apoptosis ðp < 0:025Þ compared to
serum of diabetic patients with neuropathy treatment.
The ﬁndings of the present study conﬁrm the role of nerve con-
duction studies in the assessment of diabetic neuropathy. There is
a signiﬁcant correlation between motor median nerve conduction
velocity and the progress to develop diabetic neuropathy. The ﬁnd-
ings of the current prospective study revealed for the ﬁrst time that
there is signiﬁcant correlation between sFas and the motor median
nerve conduction study. The ﬁnding that serum sFas levels were
signiﬁcantly higher in diabetics with neuropathy compared to
other groups indicates that serum sFas levels in diabetes could
be considered as a good marker for the development of peripheral
neuropathy. Moreover, the ﬁnding that the serum of diabetic pa-
tients with neuropathy could induce apoptosis in neuronal cells
in vitro indicates that Fas mediated apoptosis may have a role in
the aetiopathogenesis of diabetic neuropathy. However, animal
and human studies are needed to establish the factors that regulate
this process.
In the present work, we demonstrated for the ﬁrst time that
apoptosis induced by the serum of diabetic patients with neurop-
athy could be blocked or inhibited by antagonistic anti-Fas (ZB4)
antibody. This ﬁnding conﬁrms that the Fas-mediated apoptosis
of the neuronal cell line is responsible for the degradation of the
neurons in patients with diabetic neuropathy and provides evi-
dence for the involvement of the receptor pathway in Fas-medi-
ated apoptosis of these cells. Thus targeting and inhibiting Fas
receptor offers an option for diabetic neuropathy therapy.References
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